Industry news that matters to you.  Learn more

Rosetta Genomics Reports Study Comparing microRNA Profiles of Cancer of Unknown Primary and Metastases of Known Primary Tumors Published in Clinical Experimental Metastasis

Reading time: 3 – 5 minutes

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announced last week that data from a study assessing the differences between cancer of unknown primary (CUP) and metastatic solid tumors of known primary metastases (KPM) by profiling microRNA expression were recently published in Clinical Experimental Metastasis, in an article entitled “Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors.”

The study assessed microRNA differences between CUP metastases with favorable prognosis and metastases of known primary tumors in order to screen for an aggressive, pro-metastatic, CUP-specific biologic signature.

The study consisted of two stages. In the first stage, metastases obtained from CUP cases were assigned to a primary tissue of origin using Rosetta’s miRview(®) mets(2) microarray assay and compared to pathological and clinical presentation. In the second stage, the expression of 733 microRNAs was examined in CUP tumors classified as breast, serous ovarian and upper squamous cancers and compared to that of matched KPMs.

The study evaluated approximately 100 CUP and KPM tumors and found no unique microRNA signature differentiating CUP presentation from that of metastases of known primaries. This supports current gold standard treatment for patients with favorable prognosis CUP, who are managed similarly to those with equivalent metastatic tumors of known primary. This study was a sub-set of a larger retrospective study assessing the performance of the miRview mets(2) assay in a cohort of real CUP patients. The results of that study demonstrated that miRview mets(2) assay showed agreement with pathological and clinical information in 92% of cases. Those data have been presented at medical conferences and are expected to be published in a separate peer-reviewed journal article.

Study author, George Pentheroudakis, M.D., Department of Medical Oncology at the University of Ioannina Medical School in Ioannina, Greece, noted, “This research is the first look for microRNA characteristics of CUP tumors. Study results confirmed epidemiologic evidence suggesting that patients with favorable prognosis CUP have a presentation, response to therapy and outcome no different from metastatic tumors of matched primaries.”

“This publication demonstrates the utility of microRNA profiling in understanding the biology of CUP and may have important implications for the prognosis and treatment of CUP patients,” stated Kenneth A. Berlin, President and CEO of Rosetta Genomics. “We look forward to the publication of the full data set which we believe continues to underscore the clinical value of our miRview mets(2) assay in identifying the primary tumor type in CUP patients in order to optimize treatment protocols and potentially improve clinical outcomes.”

About Cancer of Unknown Primary Origin

According to the American Cancer Society, an estimated 2 to 5 percent of all cancer patients have metastatic (secondary) tumors for which routine testing cannot locate the primary site. This is called cancer of unknown primary origin. Patients may be diagnosed with cancer of unknown primary origin if the primary tumor is too small to be identified with routine imaging tests, it regresses (disappears) before a secondary tumor arises or the secondary tumor has several possible primary sites. Cancer of unknown primary origin can appear anywhere in the body, but is most commonly found in the lymph nodes, liver, lungs, bones or skin.

The miRview mets(2) assay measures the expression level of 64 microRNA biomarkers, which are then processed by an algorithm composed of two classifiers and a decision-maker that can accurately identify the origin of the patients’ tumor for 42 different cancer tissue types, with 85 percent sensitivity and 99 percent specificity. Clinicians use Rosetta Genomics’ assay to better diagnose CUP patients and get them on more optimal treatment plans.

Study: Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors

Source: Rosetta Genomics